tbuckley/cabot-search huggingface dataset:
When Will Mendelian Randomization Become Relevant for Clinical Practice and Public Health?
Authors: George Davey Smith, Lavinia Paternoster, Caroline Relton
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Perineural invasion as a prognostic factor in rectal cancer treated with preoperative chemoradiotherapy: A multicenter retrospective study
Authors: J.W. Park, S.-B. Ryoo, B.K. Park, S.-B. Kang, J.H. Oh, D.-W. Kim, S.-Y. Jeong, K.J. Park
Journal: Annals of Oncology (2016)
Copper-Complexed Melphalan (MOC*M), a Member of a New Class of Anti-Leukemic and Anti-Tumouric Substances for Treatment of Primary and Relapsed Acute Lymphoblastic Leukemia in Childhood.
Authors: Aram Prokop, Corazon Frias, Guenter Henze, Swetlana Sadolinnaya, Valeriy Tatarskiy
Journal: Blood (2005)
18F-FDG PET/CT Imaging of Epididymal Smooth Muscle Mass Mimicking Recurrent Lymphoma
Authors: Shogo Takeuchi, Masayuki Inubushi, Kiyohisa Nagai, Teruki Sone
Journal: Clinical Nuclear Medicine (2017)

An 84-year-old man with a history of diffuse large B-cell lymphoma in remission who had completed chemotherapy 3 years previously was referred for imaging evaluation of disease recurrence. Abnormal accumulation in the left scrotum was demonstrated on F-FDG PET/CT. Subsequent ultrasonography showed a nodular mass lesion in the left epididymis. He then underwent left orchiectomy. Histopathological examination of the mass diagnosed smooth muscle hyperplasia/hamartoma of the left epididymis. Epididymal smooth muscle hyperplasia/hamartoma should be included as a differential diagnosis for malignant scrotal tumor.
Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)
Authors: Arne Kolstad, Ulf Madsbu, Bjørg Bolstad, Caroline Stokke, Tore Bach-Gansmo, Ayca Muftuler Løndalen, Jon Erik Holtedahl, Mona Elisabeth Revheim, Øyvind Bruland, Jostein Dahle, Nils Bolstad, Roy Hartvig Larsen, Signe Spetalen, Martin Erlanson, Stine Nygaard Rudå, Harald Holte
Journal: Blood (2015)
Interest of Negative Minimal Residual Disease Estimated by Flow Cytofluorometry After Allogeneic Stem Cell Transplantation for B-Cell Chronic Lymphocytic Leukemia
Authors: Caroline Algrin, Magali Le Garff-Tavernier, Oumedaly Reman, Vincent Levy, Anne Huynh, Anne Sirvent, Alice Garnier, Madalina Uzunov, Stéphanie Nguyen, Hélène Merle-Beral, Véronique Leblond, Nathalie Dhedin
Journal: Blood (2010)
A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit
Authors: Guillermo Garcia Manero, Ehab Atallah, Samer K Khaled, Martha Arellano, Mrinal M Patnaik, Olatoyosi Odenike, Hamid Sayar, Mohan Tummala, Prapti A. Patel, Richard G. Ghalie, Bruno C. Medeiros
Journal: Blood (2016)
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience
Authors: M. Bonomi, L. Bonomi, M.G. Sauta, A.C. Bettini, M. Squadroni, F. Brena, E. Cerchiaro, C. Ripa, P. Salvini, G.D. Beretta, C. Tondini, G.L. Ceresoli
Journal: Annals of Oncology (2016)
Genetic Evidence That an 11 Amino Acid β-Hairpin Loop in the Cytoplasmic Domain of Band 3 Is Responsible for at Least 50% of Ankyrin Binding in Mouse Erythrocytes.
Authors: Nicholas O. Markham, Erin M. Parry, Marko Stefanovic, Patrick G. Gallagher, Philip S. Low, David M. Bodine
Journal: Blood (2005)
BRAF mutation and Microsatellite status in stage II and III colorectal cancers: does the combination have a prognostic role?
Authors: L. Belluomini, F. Daniel, I. Carandina, G. Galli, F. Lancia, I. Toma, L. Martella, L. Da Ros, M. Marzola, G. Lanza, A. Frassoldati
Journal: Annals of Oncology (2016)
Platelet Factor 4 Potently Inhibits Tumor Cell Growth and Angiogenesis In Multiple Myeloma
Authors: Pei Liang, Suk-Hang Cheng, Chi-Keung Cheng, Kin-Mang Lau, Natalie Pui Ha Chan, Rosalina KL Ip, Raymond S.M. Wong, Margaret H.L. Ng
Journal: Blood (2010)
Elevated Reactive Oxygen Species Production In Sickle Erythrocytes Is Modulated by a Pathway Involving Endothelin-1, TGFβ1, PKC, and Rac GTPases
Authors: Alex George, Sebastian Koochaki, Suvarnamala Pushkaran, Narla Mohandas, Yi Zheng, Clinton H. Joiner, Theodosia A Kalfa
Journal: Blood (2010)
NIMG-69. DISTINGUISHING RADIATION NECROSIS FROM BRAIN TUMOR RECURRENCE ON ROUTINE MRI: A PRELIMINARY HUMAN-MACHINE READER COMPARISON STUDY
Authors: Prateek Prasanna, Ameya Nayate, Amit Gupta, Lisa Rogers, Gagandeep Singh, Leo Wolansky, Marco Pinho, Kimmo Hatanpaa, Anant Madabhushi, Pallavi Tiwari
Journal: Neuro-Oncology (2016)

Distinguishing radiation necrosis (RN) from tumor recurrence (RT) on routine MRI is a major challenge in neuro-oncology. To date, there is no imaging modality that can reliably distinguish RT from RN. In this study, we quantitatively compare the performance of a machine learning classifier in conjunction with radiomic features (computer-extracted textures) on routine MRI (T1w, T2w, FLAIR) with the visual diagnosis of two attending neuro-radiologists in distinguishing RT from RN. 3T-MRI studies with T1w, T2w, FLAIR protocols in N=55 patients (22 RN, 33 RT) obtained at least 9 months post-chemoradiation were analyzed. 135 radiomic features (i.e. Haralick, Laws energy, histogram of gradients) within lesions were extracted for each MRI protocol. A random forest classifier was trained on N=40, and tested on N=15 using the extracted features. Independently, two expert board-certified neuro-radiologists (with 2-, and 4-years of experience) who were blinded to the pathology reports (ground truth), read the same MRI scans to diagnose the presence of RN or RT. The readers assigned a score between 0.5 (unclear) and 1 (completely confident) to each study, based on the confidence in their diagnostic reads. Analysis from classifier and radiologists' reads were compared to the pathologic findings. Area under receiver operating characteristic curve was found to be 0.79 for classifier, 0.75 for expert 1 and 0.58 for expert 2. Consensus with correct classification between the two experts was only seen in 22 of 55 studies (kappa coefficient =0.47). Our results suggest that radiomic features provide complementary diagnostic information to capture subtle differences between RT and RN on routine MRI that may not be visually appreciable to expert readers. Once validated on a larger cohort, radiomic analysis could serve as a decision support tool to enable timely and appropriate patient management in brain tumors.
Survival impact of adjuvant chemotherapy in screening breast cancer
Authors: I. Zarcos Pedrinaci, A. Romero, J. Louro, M. Banqué, M. Vernet, L. Serrano, R. Funez, F. Medina, D. Perez, A. Rueda, M. Sala, M. Redondo
Journal: Annals of Oncology (2016)
Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Authors: L. Gandhi, S. Gadgeel, A. Shaw, F. Barlesi, L. Crinò, J.C.-H. Yang, A.-M.C. Dingemans, D.-W. Kim, F. de Marinis, M. Schulz, S. Liu, S. Fish, A. Kotb, S.-H.I. Ou
Journal: Annals of Oncology (2016)
Nomograms to predict prognosis in pseudomyxoma peritonei: A Peritoneal Surface Oncology Group International (PSOGI) multicenter study.
Authors: Shigeki Kusamura, Brendan J. Moran, Paul H. Sugarbaker, Elias Dominique, Dario Baratti, Edward Allen Levine, David L. Morris, Olivier Glehen, Armando Sardi, Francois Quenet, Pedro Barrios, Brian W. Loggie, Ignace H.J.T. de Hingh, Wim P. Ceelen, Pompiliu Piso, Santiago Gonzalez-Moreno, Kurt Van der Speeten, Luigi Mariani, Rosalba Miceli, Marcello Deraco
Journal: Journal of Clinical Oncology (2014)

4033 Background: We built nomograms for predicting overall (OS) and progression-free survivals (PFS) in patients with pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS)+/-intraperitoneal chemotherapy (IPCT). Methods: Data from 1,715 PMP patients in 31 centers from 1993 to 2012 constituted the developing set. The covariates were previous systemic chemotherapy (sCT), histologic subtype (Ronnett’s criteria), peritoneal cancer index (PCI), completeness of cytoreduction (CC), IPCT (Hyperthermic intraperitoneal chemotherapy [HIPEC], early postoperative chemotherapy [EPIC], or both), lymph node status (LN), G3-5 morbidity (NCI CTCAE v3), and surgical proficiency. Centers with >100 procedures for PMP were considered proficient. Continuous variables were transformed using restricted cubic splines. We handled missing data using multiple imputation with chained equations (MICE) approach. We fitted a Cox model in each of the different completed developing datasets generated by MICE. Pooled estimates of regression coefficients, variances, and models’ discriminations (bootstrap corrected Harrell C indexes) were obtained using Rubin’s rule. The nomograms were externally validated on 733 PMP patients from two high-volume referral centers in USA (validating set). Results: In the developing set the median follow-up was 39 months. Five-year OS and PFS rates were 74.1% (95%CI: 71.3-76.8) and 52.3% (95%CI: 49.4-55.2), respectively. The means of adjusted Harrell C indexes for OS and PFS were 0.80 and 0.74 in the developing set and 0.74 and 0.72 in the validating set. In the developing set significant predictors of OS were sCT, PCI, CC, IPCT, histological subtype, LN, and G3-5 morbidity while those of PFS were surgical proficiency, sCT, histological subtype, PCI, CC, and IPCT. Conclusions: These nomograms may allow predicting OS and PFS providing individualized outcome prognostication. They would support therapeutic decision-making and stratification of future clinical trials.
Impact of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients with Neoadjuvant Chemotherapy Depends on Subtypes
Authors: Akiko Matsumoto, Hiromitsu Jinno, Hiroki Ishida, Kunihiko Hiraiwa, Tetsuya Nakamura, Yoshihito Ueyama, Junichi Saito
Journal: Annals of Oncology (2016)
Multiple Myeloma-Specific Targeted Therapy: Use of the Tumor Specific Immunoglobulin Gene Sequence to Activate Drugs Only within Tumor Cells.
Authors: Zhi-Wei Li, Dror Shalitin, Jennifer Finefield, Crystal Leung, Mengyin Hu, Jing Shen, Mingjie Li, Cathy S Wang, Jeffrey A Steinberg, Eric Sanchez, Haiming Chen, Robert M Williams, Benjamin Bonavida, James R. Berenson
Journal: Blood (2009)
P08.31 A perivascular niche for progression and resistance in glioblastoma
Authors: M. Osswald, E. Jung, S. Weil, J. Blaes, G. Solecki, F. T. Kurz, S. Heiland, P. E. Huber, W. Wick, F. Winkler
Journal: Neuro-Oncology (2016)
Influence of FASL and FAS polymorphisms, enrolled in extrinsic apoptosis pathway, in the inherited increased risk of head and neck squamous cell carcinoma
Authors: C.S.P. Lima, V.T. Liutti, T.R.P. Lima, E.F.D. Costa, L. Lopes-Aguiar, G.A.S. Nogueira, F. Leal, V.C.A. Santos, C.B.M. Oliveira, J.A. Rinck-Junior, G.J. Lourenço
Journal: Annals of Oncology (2016)
Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients
Authors: A. Santonja, B. Pajares, B. Jiménez-Rodríguez, C. Fernández-De Sousa, N. Ribelles, A. Lluch-Hernandez, I. Catoira, E. Perez-Ruiz, M. Martin, M. Del Monte-Millan, A. Gonzalez-Neira, G. Pita, M.A. Pujana, M. Ruiz, N. Bonifaci, J. De la Haba, P. Sanchez-Rovira, E. Alba, A. Romero
Journal: Annals of Oncology (2016)
EXTH-63. PRECLINICAL EFFICACY OF A CDK INHIBITOR (TG02) IN GLIOBLASTOMA
Authors: Kristine Pelton, Alice Meng
Journal: Neuro-Oncology (2016)

Radiation is the most effective treatment for glioblastoma (GBM), however tumor recurrence develops in all patients. Novel treatment strategies targeting multiple pathways in combination with radiation are needed. TG02 is an orally-bioavailable multi-kinase inhibitor of CDK5 and CDK9 targeting MYC and the Bcl-2 family survival protein, Mcl-1, both commonly overexpressed in GBM. MYC and Mcl-1 overexpression leads to increased proliferation and is associated with treatment resistance. We examined the preclinical efficacy of TG02 both as monotherapy and in combination with radiation in a panel of 10 GBM patient derived cell lines (PDCLs). TG02 treated PDCLs were subjected to luminescent ATP assays and cell viability was determined relative to DMSO control. TG02 was found to decrease cell viability in all PDCLs tested, with IC50 values ranging from 25nM to 3μM. PDCLs highly expressing Mcl-1 or MYC showed increased sensitivity to treatment with TG02. Furthermore, PDCLs treated with TG02 followed by a range of doses of ionizing radiation showed that TG02 synergizes with radiation in some but not all PDCLs, but TG02 was effective in radiation resistant lines suggesting possible hypothetical synergy in a theoretic mixed clonal population. These results provide evidence for the efficacy of TG02 against GBM patient derived cell lines and supports the development of TG02 in combination with radiation for clinical testing in glioblastoma.
Cerebral Parenchymal Photopenia on FDG-PET/CT Reflecting Vasogenic Edema Due to Leptomeningeal Metastasis in Breast Cancer
Authors: Mitsutomi Ishiyama, Manuela Christina Matesan
Journal: Clinical Nuclear Medicine (2017)

A 61-year-old woman with metastatic breast cancer presented with migrainelike episodes over the past 10 months. FDG-PET/CT(PET/CT) showed relatively symmetric areas of photopenia predominantly in the bilateral superior parietal lobules. Subsequent contrast-enhanced MRI revealed leptomeningeal metastasis in the bilateral posterior parietal regions with associated vasogenic edema in the adjacent brain parenchyma. There was no clear evidence of parenchymal metastasis on MRI. After chemotherapy, the areas of abnormality resolved on PET/CT 8 months later, and the patient showed interval symptomatic improvement. The present case demonstrates brain parenchymal photopenia on PET/CT as an indirect sign of leptomeningeal metastasis reflecting regional vasogenic edema.
Therapeutic Hypothermia After Cardiac Arrest—Reply
Authors: Paul S. Chan, John A. Spertus
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QLIF-01. PERCEIVED EFFECTIVENESS OF MANAGEMENT STRATEGIES USED BY NEURO-ONCOLOGY FAMILY CAREGIVERS
Authors: Mary C. Roberge, Susan H. Hughes, Jason Weimer, Susan Misko, Terri Armstrong, Paula Sherwood, Heidi Donovan
Journal: Neuro-Oncology (2016)

Family caregivers (CG’s) of patients with primary malignant brain tumors (PMBT) face psychological and physical health challenges as a consequence of providing this level of care. These CG’s are high-risk for poor outcomes as they manage both cancer-related and neurodegenerative-related issues. SmartCare© (R01 NR013170) is a 3-arm randomized-controlled trial testing an Internet- and telephone-based caregiver support intervention. This analysis presents the most common care issues worked on by CG’s in the intervention arm, types of strategies used to manage issues, and types of strategies perceived as most effective. Of the 66 CG’s randomized to SmartCare© intervention, 33 CG’s selected issues, wrote goals, developed strategies and evaluated the effectiveness of these strategies. Individual CG strategies were classified according to seven dimensions of the Health Education Impact Questionnaire, an evaluation measure for psycho-educational interventions. Caregivers selected 22 of 32 possible issues during intervention. The four most-commonly chosen issues were: maintaining CG emotional health, maintaining CG physical health, managing patient muscle weakness (each n=6; 10.5%), and changes in patient thinking and behavior (n=5; 8.8%). Caregivers worked on an average 1.6+/-0.79 issues during the intervention and used 4+/-1.56 types of strategies. Most common strategy-types used were Health-Directed Behaviors (e.g. exercise), Skill Acquisition, and Healthcare Navigation. The type of strategy with the highest effectiveness rating was Positive and Active Engagement in Life (e.g. taking a break from caregiving) (8.13+/-1.66); the strategy rated least effective was Skill Acquisition (6.82+/-2.93). Understanding how family caregivers select and use management strategies to effectively work to manage care is critical to advancing the science of caregiver interventions.
Harms of outcome switching in reports of randomised trials: CONSORT perspective
Authors: Douglas G Altman, David Moher, Kenneth F Schulz
Journal: BMJ (2017)

The outcomes reported for trials often differ from those specified in the protocol. <b>Douglas Altman</b>, <b>David Moher</b>, and <b>Kenneth Schulz</b> call for journals to do more to ensure that authors follow guidelines
monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer
Authors: S.M. Tolaney, N. Bourayou, S. Goel, T. Forrester, F. André
Journal: Annals of Oncology (2016)
Both DOCK180 and DOCK2 Participate in the CXCL12 and CCL19 Dependent Chemotaxis of Human Dendritic Cells Derived From Monocytes Through the Activation of Rac
Authors: Hideki Goto, Mitsufumi Nishio, Katsuya Fujimoto, Tomoyuki Endo, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hiroshi Nishihara, Takao Koike, Masahiro Imamura
Journal: Blood (2011)
MPTH-05. RAPID AUTOPSY PROGRAM FOR PEDIATRIC NEURO-ONCOLOGY
Authors: Katharine Rae, Cheryl Fischer, Prajwal Rajappa, Scott Connors, David Pisapia, Jeffrey Greenfield, Yasmin Khakoo
Journal: Neuro-Oncology (2016)

This report details a bi-institutional collaborative effort in coordinating a rapid autopsy as part of a precision medicine umbrella program, for a pediatric patient who died at home. We outline a procedure for obtaining a rapid autopsy in order to collect high quality post mortem tissue for genomic analysis. We discuss the scientific rationale for offering a rapid autopsy to caregivers of pediatric patients as well as parental perspectives on broaching the subject of autopsy. We then review the logistics and coordination involved with planning a rapid autopsy and sequence of events needed to maximize tissue quality. We report the successful coordination of a rapid autopsy for a patient who died in the hospice setting at her out-of-state home. The time interval from death to start of the rapid autopsy procedure was 4.5 hours, despite the logistical considerations demanded by the location of the patient. Tumor aliquots and non-neoplastic tissues were successfully snap frozen for downstream genomic studies. Physicians should consider trialing a rapid autopsy program at their institution to offer to caregivers of pediatric oncology patients. This report offers a framework to help clinicians develop their own rapid autopsy programs as well as guidelines to help streamline this process for appropriate candidates going forward.
Preparation technique for cytologic study of EUS-guided FNA samples when onsite cytopathologist is absent: Cell block, smear, or both?
Authors: N. Q. Nguyen, K. Lim, A. Ruszkiewicz
Journal: Journal of Clinical Oncology (2011)

176 Background: Smearing EUS-guided fine-needle aspiration (FNA) samples, with or without cell block, is most commonly performed for cytologic study in centers without onsite cytology. The diagnostic yield of such technique is often low (35%-50%) and may be related to loss of diagnostic material during the smearing process. Cell block technique captures not only aspirated cells but also small tissue fragments, improving diagnostic yield and enabling additional ancillary studies. This study aimed to compare the diagnostic yield of cell block alone against conventional smear (±cell block) technique in the EUS-guided FNA evaluation of pancreatic solid mass without onsite cytological assessment. Methods: Data on the diagnostic yield of cell block alone technique performed over the last 12 months were prospectively collected and were compared to the yield of conventional smear ± cell block technique. A positive diagnostic yield was defined by the presence of adenocarcinoma and/or FNA findings consistent with the final surgical diagnosis. Results: Data were available for 96 patients, of which 66 had cell block alone and 30 had smear +/-cell block preparation. The diagnostic yield of cell block alone was significantly higher that that of smear +/- cell block (53/66 vs 13/30; P=0.003). The addition of cell block after smearing did not improve the diagnostic yield (smear: 42% vs. both: 45%, p=0.88). Of patients who had smear +/-cell block, the diagnostic yield was significantly higher when the smearing was performed by cytopathologist as compared to that by nurse (10/16 vs. 3/14, p=0.02). There was a direct relationship between the rate of diagnostic yield and the number of FNA passes performed. The yield was highest when 4 or more FNA passes was performed (85%) as compared to that of 3 passes (63%, p=0.049) and 2 or less passes (38%, p&lt;0.0001). Conclusions: In the absence of onsite cytology services, the diagnostic yield from cell block alone was high (80%) and was superior to smear technique whether cell block was added to the evaluation of smears. In order to obtain adequate tissue material to maximise the diagnostic yield EUS-guided FNA of pancreatic mass, at least 4 FNA passes should be performed. No significant financial relationships to disclose.